CoChat

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis

Open access
Ma, Hong, Lin, Yu-Hao, Dai, Li-Zhen, Lin, Chen-Shi, Huang, Yanling, Liu, Shu-Yuan · 2023 · BMJ Open
Cited by 104

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Objective: To compare the efficacy and safety between and within glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in overweight or obese adults with or without diabetes mellitus. Methods: PubMed, ISI Web of Science, Embase and Cochrane Central Register of Controlled Trials database were comprehensively searched to identify randomised controlled trials (RCTs) of effects of GLP-1RAs and SGLT-2is in overweight or obese participants from inception to 16 January 2022. The efficacy outcomes were the changes of body weight, glucose level and blood pressure. The safety outcomes were serious adverse events and discontinuation due to adverse events. The mean differences, ORs, 95% credible intervals (95% CI), the surface under the cumulative ranking were evaluated for each outcome by network meta-analysis. Results: Sixty-one RCTs were included in our analysis. Both GLP-1RAs and SGLT-2is conferred greater extents in body weight reduction, achieving at least 5% wt loss, HbA1c and fasting plasma glucose decrease compared with placebo. GLP-1RAs was superior to SGLT-2is in HbA1c reduction (MD: −0.39%, 95% CI −0.70 to −0.08). GLP-1RAs had high risk of adverse events, while SGLT-2is were relatively safe. Based on intraclass comparison, semaglutide 2.4 mg was among the most effective interventions in losing body weight (MD: −11.51 kg, 95% CI −12.83 to −10.21), decreasing HbA1c (MD: −1.49%, 95% CI −2.07 to −0.92) and fasting plasma glucose (MD: −2.15 mmol/L, 95% CI −2.83 to −1.59), reducing systolic blood pressure (MD: −4.89 mm Hg, 95% CI −6.04 to −3.71) and diastolic blood pressure (MD: −1.59 mm Hg, 95% CI −2.37 to −0.86) with moderate certainty evidences, while it was associated with high risk of adverse events. Conclusions: Semaglutide 2.4 mg showed the greatest effects on losing body weight, controlling glycaemic level and reducing blood pressure while it was associated with high risk of adverse events. PROSPERO registration number CRD42021258103.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2022-061807

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 19 references

Cited by

See all 104

Metadata

Authors
Ma, H., Lin, Y.-H., Dai, L.-Z., Lin, C.-S., Huang, Y., & Liu, S.-Y.
Venue
BMJ Open
Publisher
BMJ
Published
2023-03
Volume
13
Issue
3
Pages
e061807
ISSN
2044-6055 (ISSN-L)
OpenAlex
W4323356536
Cited by
104
References
19
FWCI
6.06
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2022-061807
The paper
Ma, H., Lin, Y.-H., Dai, L.-Z., Lin, C.-S., Huang, Y., & Liu, S.-Y. (2023). Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2022-061807

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.